Top Stories
Gilead Sweeps First-Line TNBC with Dual Phase 3 Wins for Sacituzumab Govitecan
Gilead delivered a one-two punch in first-line triple-negative breast cancer, with sacituzumab govitecan combinations hitting primary endpoints in both ASCENT-03 and ASCENT-04 trials, according to CancerNetwork. The ASCENT-04 study tested sacituzumab govitecan plus pembrolizumab against standard chemotherapy plus pembrolizumab in PD-L1-positive patients, while ASCENT-03 evaluated the ADC as monotherapy versus chemotherapy in patients unable to receive PD-L1 inhibitors. These back-to-back wins position Gilead to challenge the current first-line TNBC standard of care dominated by immunotherapy combinations from Merck and Roche. The dual approvals would give Gilead coverage across both PD-L1-positive and PD-L1-negative first-line TNBC populations, potentially capturing 60-70% of the roughly 50,000 annual US cases. Gilead now owns both pembrolizumab-eligible and ineligible first-line TNBC segments Roche and AstraZeneca lose differentiation as TNBC becomes an ADC-first market
BeOne Medicines Axes Five Cancer Programs in Pipeline Purge
BeOne Medicines delivered a brutal pipeline cull, dropping five Phase 1 cancer programs and halting a Phase 2 rheumatoid arthritis trial based on disappointing new data, Fierce Biotech reported. The biotech eliminated programs across its early oncology portfolio while retaining only its most advanced assets. This marks one of the more aggressive pipeline restructurings seen in 2026, suggesting BeOne is conserving cash for fewer but higher-probability shots. The move follows a pattern of biotechs ruthlessly cutting lower-conviction programs as funding tightens and investors demand clearer paths to value inflection. BeOne joins companies like Karyopharm and Forma Therapeutics in making tough portfolio decisions rather than spreading resources too thin. The surviving programs will need to deliver compelling data quickly to justify the strategic focus. BeOne shareholders see 5 potential value drivers eliminated in single decision Remaining BeOne programs get concentrated resources and management attention
Pipeline Watch
OncLive polling reveals top lung cancer abstracts generating pre-meeting buzz at ASCO 2026, per OncLive. The preview highlights suggest major data readouts in NSCLC and SCLC that could reshape treatment paradigms. Key areas of focus include novel IO combinations, targeted therapies, and ADC platforms. The polling provides early insight into which studies oncologists expect to move practice patterns.
OncLive released poll results highlighting breast cancer abstracts of highest interest ahead of ASCO 2026, according to OncLive. The polling identified key studies across hormone-positive, HER2-positive, and triple-negative breast cancer segments. Results suggest significant data readouts expected in CDK4/6 combinations, antibody-drug conjugates, and novel targeted approaches. The preview indicates ASCO 2026 could feature multiple practice-changing breast cancer studies.
ECOG-ACRIN launched recruitment for a study combining apalutamide with PET-guided targeted radiation in biochemically recurrent prostate cancer, per ClinicalTrials.gov. The trial tests whether adding targeted radiation to standard androgen receptor inhibition improves outcomes. The study represents growing interest in combining systemic therapy with precision radiotherapy approaches in prostate cancer management.
Dario Trapani from European Institute of Oncology discussed enhanced collaboration between AIFA and AIOM to improve oncology drug access in Italy, according to OncoDaily. The partnership aims to streamline regulatory pathways while maintaining rigorous safety standards. The initiative could serve as a model for other European markets seeking to balance innovation access with cost containment.
Rasha Aboelhassan from Nasser Institute Hospital raised questions about optimal AI dependence levels for practicing oncologists, per OncoDaily. The discussion reflects ongoing uncertainty around AI tool integration in clinical decision-making. As AI platforms proliferate in oncology, defining appropriate physician-AI collaboration remains a key challenge for healthcare systems globally.
Daiichi Sankyo entered a collaboration with Paris-based Waiv to apply digital pathology biomarker discovery to one of its antibody-drug conjugate (ADC) programs, per Pharmaceutical Technology (May 7, 2026). Waiv will use its computational pathology platform to analyze tumor microenvironments via H&E and IHC stained samples, aiming to identify biomarkers linked to treatment response ahead of upcoming clinical trial phases. The partnership underscores Daiichi Sankyo's continued investment in pairing AI-driven patient selection with its industry-leading ADC franchise.
UCB entered an expanded multi-project strategic alliance with Cancer Research UK and its innovation arm Cancer Research Horizons, building on a 2023 collaboration that has already advanced two antibody candidates into ongoing clinical trials, according to PharmaTimes (May 7, 2026). The expanded framework adds two UCB-nominated programs and brings earlier-stage discovery and preclinical work into the partnership, with CRUK's Centre for Drug Development designing and sponsoring phase 1/2 trials. UCB retains exclusive commercialization rights, while Cancer Research Horizons will receive undisclosed milestone and royalty payments.
Competitive Landscape
Gilead's ASCENT wins establish sacituzumab govitecan as the ADC frontrunner in first-line TNBC, pressuring Daiichi Sankyo and AstraZeneca to accelerate their TNBC programs. Gilead captures first-mover advantage in lucrative first-line setting Late ADC entrants face higher efficacy bar
| Company | TNBC ADC | Line of Therapy | Status |
|---|---|---|---|
| Gilead | Sacituzumab Gov | 1L (Ph3 readout) + 2L+ (Approved) | Filing expected |
| Daiichi Sankyo | T-DXd | 2L+ | Phase 3 |
| AstraZeneca | Datopotamab | 1L | Phase 3 |
BeOne's decision to eliminate five cancer programs reflects a broader biotech trend toward ruthless portfolio prioritization as funding constraints intensify. Companies choosing focused bets over diversified pipelines to maximize remaining runway, per Fierce Biotech analysis.
Polling interest in both lung and breast cancer abstracts indicates ASCO 2026 could feature multiple practice-changing readouts across solid tumor indications. High physician engagement suggests significant competitive dynamics ahead, according to OncLive surveys.
Forward Looking
- Watch for Gilead regulatory filings in first-line TNBC as dual ASCENT wins position company to challenge current IO-chemo standards
- ASCO 2026 abstract release on May 14, 2026 will reveal which companies have practice-changing data to present at the May 29-June 2 Chicago meeting
- Expect more biotech pipeline cuts as funding market remains challenging and investors demand portfolio focus over breadth
- Monitor competitive ADC positioning as Daiichi Sankyo and AstraZeneca respond to Gilead's first-line TNBC success